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Previews(such as IL-2, IL-7, IL-15), Th2 cell-asso-
ciated cytokines, hypoxia, and estradiol
(Stephen et al., 2014). Altogether, these
findings underscore the relative ‘‘speci-
ficity’’ of the TGF-b-Foxp1 pathway.
The present work might have important
clinical implications. Inhibition of TGF-b
and its signaling pathway with antibodies
or antisense oligonucleotides or anti-
sense molecules targeting TGF-bRI or
RII is one possible strategy for boosting
anticancer immune responses. Adoptive
transfer of cytotoxic T lymphocytes engi-
neered to express a dominant-negative
mutant of the TGF-b receptor is also in
early development. As an alternative, the
emerging, ever-more practical genome-
editing technologies (such as transcrip-
tion-like effector nucleases and clustered
regularly interspaced short palindromicrepeats) might be used to engineer
T cells without TGF-b receptor subunits
or downstream effectors including
FOXP1 (Figure 1). Finally, the facts that
FOXP1 must cooperate with other tran-
scription factors including SMAD2 and
SMAD3 and simultaneously must antago-
nize FOXO1 might be taken advantage of
to create small molecules that disrupt
specific protein-protein or protein-DNA
interactions with the scope of creating a
new category of checkpoint blockers.REFERENCES
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The hallmark of bubonic plague is the presence of grotesquely swollen lymph nodes, called buboes.
This frenzied inflammatory response to Yersinia pestis is poorly understood. In this issue of Immunity,
St. John et al. (2014) explore the mechanism by which Y. pestis spreads and thus leads to this striking lymph-
adenopathy.In anticipation of microbial infections, the
dendritic cell (DC) acts as an early immune
detection system in tissue sites. Upon
encounter with a microbe, DCs quickly
mature and traffic to local draining lymph
nodes (dLNs), where they interact with
T cells and B cells to promote the devel-
opment of adaptive immunity. Simulta-
neously, neutrophils, monocytes, macro-
phages, and additional phagocytic cells
infiltrate tissues and attempt to eliminate
the microorganism before the adaptive
response is fully engaged. After clonal
expansion in LNs, lymphocytes also traffic
to sites of infection to combat pathogens.
Receptors and signaling molecules are
involved at every step along this processwith the goal of orchestrating an effective
immune response by multiple immune
cells.
These layers of protection appear
ideally suited to stop pathogens in their
tracks, but could the migration of cells
involved in immune defense collaborate
with the pathogen to support the progress
of disease? Certainly it appears that way
with HIV, in which DCs carrying intact vi-
rus traffic to LNs to deliver the microbe
to a site rich in susceptible host cells.
Bacterial pathogens that preferentially
replicate within lymphoid tissue, such as
Salmonella and Yersinia species, could
also follow this model, but the cellular ba-
sis for their migration into these tissues ispoorly understood (Viboud and Bliska,
2005; Zhang et al., 2008a; Zhang et al.,
2008b). In this issue of Immunity, St.
John et al. (2014) show that DCs play an
important role in delivering Yersinia pestis
into regional LNs, whereas other pha-
gocytic cells promote inter-LN spread
and thus support disease progression of
Y. pestis.
The terrifying bubonic plague, respon-
sible for the elimination of large portions
of the European population during epi-
demic outbreaks, is a consequence of
Y. pestis inoculation by infected fleas. An
impressive sign of disease is the bubo,
which is the result of an apparent unre-
strained swelling of LNs proximal to theptember 18, 2014 ª2014 Elsevier Inc. 347
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Figure 1. After Inoculation, InfectedDCsAreRecruited from the Periphery to Primary LNs via
CCR7 and S1PRs, where They Produce CCL2 and Recruit Monocytes via CCR2 and S1PRs to
Primary dLNs
Infected monocytes transport bacteria intracellularly to secondary LNs, where they begin to replicate
extracellularly and spread to the bloodstream and tissue sites. Trafficking of infected monocytes
(CX3CR1
+) between primary and secondary LNs via the receptor S1P1 is particularly important in disease
progression.
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Previewsfleabite. Dissemination from the swollen
node to additional tissue sites can lead
to other forms of disease, including pneu-
monic plague, which is highly contagious
and usually lethal in the absence of antimi-
crobial therapy. Little is known about what
occurs between inoculation and bubo for-
mation, in part because Y. pestis disease
typically progresses so quickly that it is
difficult to assess early events. For this
reason, the study by St. John et al.
(2014) is something of a breakthrough
and gives us insight into how the relatively
innocuous bite of a flea can lead the path-
ogen to target regional LNs and cause
dramatic swelling in the targeted organ.
The authors used an attenuated strain
of Y. pestis defective in iron acquisition,
which slows bacterial replication in iron-
depleted tissues, allowing the workers to
examine events that would normally
happen too quickly for visualization. In
this model, bubo formation occurred by
24 hr, and immune cells harboring in-
tracellular bacteria could be visualized
within dLNs, similar to what is typically
described for clinical infections (Butler,
1994). Using bacteria expressing orange
fluorescent protein, they found a temporal
separation in the targeting of host cells by
bacteria: DCs represented the niche
assumed by bacteria at early time points
by delivering bacteria into dLNs, and a
subsequent temporally distinct shift to
monocyte and macrophage association
drove movement between LNs. DCs
were recruited to dLNs via the chemokine
receptor CCR7, and DC recruitment was348 Immunity 41, September 18, 2014 ª2014necessary for CCL2 production and sub-
sequent monocyte recruitment, indicating
that DCs play two roles in this process.
First, they support initial bubo formation
by causing bacteria to target dLNs. Sec-
ond, their chemokine production recruits
cell types that support the spread of bac-
teria throughout the lymphatic system
(Figure 1). The absence of CCR7 signifi-
cantly improved disease outcome by
lowering bacterial replication and spread
to other tissue sites. In comparison, there
was only minor attenuation in Ccr2/
mice, indicating that the ability of DCs to
recruit macrophages and monocytes is
most likely secondary to their primary
role in supporting bacterial transport to
dLNs. The caveat to these experiments,
of course, is that all assays involved the
slow-growing mutant, and it remains un-
clear whether fully virulent strains also
require DCs for spread. In addition, the in-
fectious doses used in these experiments
are many orders of magnitude larger than
what is typically analyzed in the mouse
model. In spite of these technical issues,
the results are indeed remarkable and
connect disease processes promoted by
bacterial pathogens to those normally
associated with viral diseases, such as
HIV.
The spread of Y. pestis from LNs to
other sites, as occurs in pneumonic
plague, requires that the microorganism
break through the cellular response and
move systemically. This could result from
dLN tissue damage leading to blood-
stream access and systemic spread. InElsevier Inc.this mouse model, the vasculature sur-
rounding the dLN appeared intact despite
excessive inflammation, suggesting that
there might be a cellular route for spread.
Phagocyte populations have been iso-
lated throughout the lymphatic vascula-
ture (Bell, 1979), indicating that they
have the ability to move from primary
dLNs and potentially spread microbes.
The authors show in this model that
Y. pestis hijacks this internodal phagocyte
trafficking pathway as well to directly
deliver intracellular bacteria to secondary
LNs and promote spread. There was evi-
dence of extracellular growth of bacteria
within the secondary LNs, which could
promote passive movement of bacteria
through LNs to the bloodstream (Figure 1).
T and B cells act as sentinel cells within
secondary lymphoid organs, such as the
spleen, LNs, and Peyer’s patches, by
constantly surveying the lymphatic system
for antigen presentation by phagocytic
cells. Lymphocyte egress from these or-
gans is primarily regulated by sensing of
extracellular sphingosine-1-phosphate
(S1P), which binds S1P receptors (S1PRs)
(Cyster and Schwab, 2012). S1PRs come
in five isoforms and are differentially ex-
pressed on various cell types, including
phagocytes, arguing that these receptors
are important for inter-LN movement by
phagocytes. DC migration to and from
LNs requires the S1PRs S1P3 and/or
S1P1 (Rathinasamy et al., 2010), although
there is little information on the roles of
S1PRs in the migration of other phagocyte
populations.
To address the role of S1PRs in phago-
cyte egress from the LNs, St. John et al.
used the pan S1PR inhibitor FTY720 to
show that S1PRs play an important role
in the migration of infected phagocytes
from the periphery to primary dLNs, as
well as in inter-LN traffic. This indicated
that DCmigration to dLNs occurs through
multiple pathways, two of which are
sensed by CCR7 and S1PRs. The impor-
tance of S1PR-dependent mononuclear
cell migration in mediating bacterial
spread was emphasized in this work by
the fact that elimination of S1P1 expres-
sion, specifically within mononuclear
cells, interfered with disease progression
(Figure 1).
The results presented in this manu-
script indicate that DCs play a dual role
in collaborating with Y. pestis to promote
lymphadenopathy and disease spread:
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Previewsthey transport bacteria from tissue sites to
initiate bubo formation and, via the pro-
duction of chemokines, recruit mono-
cytes that allow the spread of bacteria to
secondary LNs. However, these two roles
for DCs might not be unique to this cell
type. Monocyte subsets can also traffic
to LNs, raising the possibility that they
could similarly initiate entry from tissues
into dLNs (Jakubzick et al., 2013). The au-
thors’ experiments with an S1P1 inhibitor
argue that internodal trafficking is most
likely the main contribution of monocytes
to disease progression, thus providing a
simple two-cell model of DC-mediated
initial dLN entry followed by monocyte-
mediated secondary LN spread.
The ability to block migration of host
cells, either from the periphery to dLNs
or between LNs, could be an important
therapeutic result. In this study, mice
were treated with FTY720 prior to and
during infection with Y. pestis, and it
would be interesting to see whether
administration following inoculation couldalso block LN egress. Spread to second-
ary LNs occurred within 24 hr postinocu-
lation in the model of St. John et al., so it
remains unclear whether it is feasible to
apply this treatment regimen to prevent
disease progression. It is also unclear
whether host-cell-dependent egress
continued after 24 hr postinoculation
because many bacteria were found extra-
cellularly at later time points. Even so, if
pharmacological inhibitors can block the
spread of the disease within the host,
they could be powerful adjuvants used
in combination with antimicrobials to limit
spread and slow bacterial growth. This
mouse model, utilizing an attenuated
strain that affects the kinetics of disease
progression, will most likely provide a
platform for further experiments to
address the efficacy of therapeutic treat-
ment options.REFERENCES
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In this issue of Immunity, Oh et al. (2014) reveal an unappreciated facet of how the microbiota influences
immune responses. Immunity to nonadjuvanted vaccines depends on Toll-like-receptor-5-mediated sensing
of the microbiota.The distal gut is colonized with an aston-
ishing 1012 bacteria per gram of gut con-
tent. Other body surfaces are also colo-
nized by microbes, which are collectively
referred to as the microbiota. The term
‘‘supraorganism’’ has been coined to
describe the fact that we are ‘‘running fer-
menters,’’ carrying numerically more bac-
teria than we have cells in our body. How-
ever, we are only beginning to understand
the impact of the microbiota on health.
Perhaps not surprisingly, the micro-
biota constantly produce and releasepotent immunostimulatory molecules,
which significantly affect the immune
system. Thus, germ-free animals, i.e.,
animals bred in the absence of any viable
microbes, show substantial differences in
their intestinal mucosal immune system;
such differences include underdeveloped
Peyer’s patches, very few plasma cells,
and reduced numbers of T cells. An
exciting new development comes with
the emerging mechanistic understanding
of the influence of the microbiota on the
host’s immune system. Strikingly, effectsare not restricted to the colonized
mucosal tissue but are also observed
at systemic body sites. For example,
the gut microbiota has been shown to
affect neutrophil maturation in the bone
marrow, susceptibility to type 1 diabetes,
and experimental encephalomyelitis. In
this issue of Immunity, Oh et al. (2014)
show that the gut microbiota can impact
vaccination to flu.
Two seasonally administrated flu
vaccines are available in the USA: a
nonadjuvanted subunit vaccine (trivalentptember 18, 2014 ª2014 Elsevier Inc. 349
